XERS — Xeris Biopharma Holdings, Inc. stock price, charts and financials

Latest market price

8.13

+0.05+0.62%

Overview Short InterestFilings

XERSQT72Xeris Biopharma Holdings, Inc.·NASDAQ

Overview Short InterestFilings

8.13+0.62%

Loading chart...

Screen all →

IOVA+6.14%$4.32 FTRE-1.20%$18.94 SLS+12.09%$11.22 URGN+0.92%$38.59 MESO+2.12%$14.47 TSHA-1.37%$5.78 TYRA+0.50%$32.04 AUPH-2.08%$14.57

Snapshot

Index	-	P/E	114.12	EPS (ttm)	0.07	Insider Own	11.71%	Shs Outstand	172.64M	Perf Week	-2.88%

Market Cap	1.39B	Forward P/E	22.22	EPS next Y	0.36	Insider Trans	-1.54%	Shs Float	164.66M	Perf Month	1.00%

Enterprise Value	1.32B	PEG	0.01	EPS next Q	-	Inst Own	-	Short Float	6.12%	Perf Quarter	31.81%

Income	12.14M	P/S	4.43	EPS this Y	107.34%	Inst Trans	-	Short Ratio	5.42	Perf Half Y	11.60%

Sales	314.85M	P/B	105.90	EPS next Y	150.50%	ROA	3.06%	Short Interest	10.08M	Perf YTD	2.93%

Book/sh	-	P/C	28.39	EPS next 5Y	66.86%	ROE	735.00%	52W High	10.14 -19.84%	Perf Year	57.50%

Cash/sh	-	P/FCF	29.54	EPS past 3/5Y	-	ROIC	12.84%	52W Low	4.90 65.91%	Perf 3Y	231.15%

Dividend Est.	-	EV/EBITDA	28.63	Sales past 3/5Y	38.46% 70.95%	Gross Margin	81.59%	Volatility	3.08% 4.07%	Perf 5Y	140.48%

Dividend TTM	-	EV/Sales	4.19	EPS Y/Y TTM	118.92%	Oper. Margin	11.40%	ATR (14)	0.31	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	1.50	Sales Y/Y TTM	55.17%	Profit Margin	3.81%	RSI (14)	49.22	Recom	2.10

Dividend Gr. 3/5Y	-	Current Ratio	2.12	EPS Q/Q	116.67%	SMA20	-4.60%	Beta	0.72	Target Price	8.82

Payout	0.00%	Debt/Eq	2.87	Sales Q/Q	38.33%	SMA50	8.37%	Rel Volume	0.86	Prev Close	8.08

Employees	435	LT Debt/Eq	2.29	Earnings	Aug 06	SMA200	14.09%	Avg Volume	1.89M	Price	8.13

IPO Date	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	464.56% 3.28%	Net Debt/EBITDA	-1.61	Volume	1,623,703	Change	0.62%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Dec-08-25	Initiated	Barclays	Overweight	$9.00
Oct-29-25	Reiterated	Oppenheimer	Outperform	$5.00 → $18
Mar-07-25	Reiterated	Piper Sandler	Neutral	$3.00 → $4.00
Nov-11-24	Reiterated	HC Wainwright & Co.	Buy	$6.60
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Oct-23-24	Reiterated	Oppenheimer		$5.00
May-10-24	Reiterated	Piper Sandler	Overweight	$3.00
Apr-28-22	Reiterated	Craig-Hallum	Buy	$6.50

Latest News

Jul-23-26

Jul-23-2608:00AM

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026gurufocus.com

Jul-08-26

Jul-08-2611:40AM

Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?zacks.com

Jul-02-26

Jul-02-2611:00PM

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)gurufocus.com

04:05PM

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)businesswire.com

Jun-30-26

Jun-30-2607:00AM

Xeris Announces Updates to Its Board of Directorsbusinesswire.com

Jun-11-26

Jun-11-2604:40PM

Xeris Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Regarding Its Patent Application Entitled Compositions And Methods Of UseBenzinga

07:09AM

Xeris Biopharma Enters Separate Exchange Agreements With Certain Holders Of Its 8.00% Convertible Senior Notes Due 2028 To Retire ~$23M Of The Notes For ~$23M In Cash And A Number Of SharesBenzinga

Company

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	315	292	203	164	110	50	20	3	2
Cost of Goods Sold Incl. D&A	58	53	37	29	23	13	9	2	0
Gross Profit	257	238	166	135	88	36	11	1	2
Selling, General and Administrative Excl. Other	191	182	163	146	138	126	74	63	21
Research and Development	32	31	26	22	21	25	21	60	41
Other Operating Expense	-2	1	11	11	11	0	0	0	0
Operating Income	36	25	-34	-44	-82	-115	-84	-122	-59
Interest Expense	28	29	33	27	14	7	7	7	3
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	4	5	10	7	0	0	0	4	2
Net Income Before Taxes	12	1	-57	-64	-96	-123	-91	-126	-60
Income Taxes	0	0	-2	-1	-1	0	0	0	0
Consolidated Net Income	12	1	-55	-62	-95	-123	-91	-126	-60
Net Income From Continuing Operations	12	1	-55	-62	-95	-123	-91	-126	-60
Net Income	12	1	-55	-62	-95	-123	-91	-126	-60
EPS (Recurring)	0.07	0.00	-0.37	-0.45	-0.70	-1.55	-2.14	-3.49	-4.99
EPS (Basic, Before Extraordinaries)	0.07	0.00	-0.37	-0.45	-0.70	-1.55	-2.14	-3.49	-4.99
EPS (Diluted)	0.07	0.00	-0.37	-0.45	-0.70	-1.55	-2.14	-3.49	-4.99
EBITDA	46	13	-14	-24	-69	-114	-79	-118	-57
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	116.14	2,453.12	—	—	—	—	—	—	—
Price To Sales Ratio	4.41	4.30	2.45	1.98	1.64	4.63	10.58	61.10	102.00
Gross Margin	81.59	81.51	81.77	82.32	80.00	72.00	55.00	33.33	100.00
Operating Margin	11.43	8.56	-16.75	-26.83	-74.55	-230.00	-420.00	-4,066.67	-2,950.00
Net Margin	3.81	0.34	-27.09	-37.80	-86.36	-246.00	-455.00	-4,200.00	-3,000.00
Shares Outstanding	171	160	147	138	136	79	43	26	12
Market Capitalization	1,390	1,256	498	324	181	231	212	183	204
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pieper Steven	See Remarks	Jul 07 '26	Sale	8.52	27,600	235,276	1,366,053	Jul 07
Pieper Steven	See Remarks	Jul 06 '26	Sale	8.50	17,400	147,900	1,393,653	Jul 07
Hecht Beth	See Remarks	Jul 01 '26	Sale	8.03	16,666	133,860	1,161,128	Jul 02
McCulloch Kevin	See Remarks	Jul 01 '26	Sale	8.03	90,000	722,511	1,691,126	Jul 02
HALKUFF DAWN	Director	Jun 04 '26	Sale	6.09	20,000	121,886	95,000	Jun 05
BORMANN-KENNEDY BARBARA-JEAN ANNE	Director	Jun 04 '26	Sale	6.09	16,000	97,507	126,500	Jun 05
JOHNSON JOHN	Director	Jun 04 '26	Sale	6.09	15,000	91,422	683,083	Jun 05
PERSKY MARLA	Director	Jun 03 '26	Sale	5.90	15,500	91,433	126,500	Jun 05
Hecht Beth	See Remarks	Jun 01 '26	Sale	6.06	16,667	100,982	1,176,506	Jun 02
Hecht Beth	See Remarks	May 01 '26	Sale	6.23	16,667	103,805	1,193,173	May 01
Hecht Beth	See Remarks	Apr 01 '26	Sale	5.99	16,667	99,859	1,209,840	Apr 03
Brady James Aloysius	Director	Mar 30 '26	Sale	5.54	10,834	60,036	89,166	Apr 01
McCulloch Kevin	See Remarks	Mar 12 '26	Option Exercise	4.09	48,898	199,992	1,777,725	Mar 16
Pieper Steven	See Remarks	Mar 05 '26	Option Exercise	4.71	41,927	197,307	1,408,940	Mar 05
Hecht Beth	See Remarks	Mar 02 '26	Sale	6.25	16,667	104,086	1,226,507	Mar 04

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.